A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related Pain
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Bowel movement within 4 hours after the first dose. Collection of adverse events, vital signs measurements, and laboratory assessments.
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
|Pfizer Investigational Site||Blendora, California 91740|
|Pfizer Investigational Site||Asheville, North Carolina 28801|
|Pfizer Investigational Site||Milwaukee, Wisconsin 53215|